Cyclopharm Ltd (CYC) - Net Assets

Latest as of December 2025: AU$27.11 Million AUD ≈ $19.18 Million USD

Based on the latest financial reports, Cyclopharm Ltd (CYC) has net assets worth AU$27.11 Million AUD (≈ $19.18 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$46.10 Million ≈ $32.62 Million USD) and total liabilities (AU$18.99 Million ≈ $13.44 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Cyclopharm Ltd tangible equity quality to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	AU$27.11 Million
% of Total Assets	58.81%
Annual Growth Rate	4.45%
5-Year Change	-37.05%
10-Year Change	117.55%
Growth Volatility	58.97

Cyclopharm Ltd - Net Assets Trend (2005–2025)

This chart illustrates how Cyclopharm Ltd's net assets have evolved over time, based on quarterly financial data. See Cyclopharm Ltd defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Cyclopharm Ltd (2005–2025)

The table below shows the annual net assets of Cyclopharm Ltd from 2005 to 2025. For live valuation and market cap data, see market cap of Cyclopharm Ltd.

Year	Net Assets	Change
2025-12-31	AU$27.11 Million ≈ $19.18 Million	-36.55%
2024-12-31	AU$42.73 Million ≈ $30.23 Million	+32.46%
2023-12-31	AU$32.26 Million ≈ $22.83 Million	-11.71%
2022-12-31	AU$36.54 Million ≈ $25.85 Million	-15.16%
2021-12-31	AU$43.07 Million ≈ $30.47 Million	+151.62%
2020-12-31	AU$17.12 Million ≈ $12.11 Million	-26.24%
2019-12-31	AU$23.20 Million ≈ $16.42 Million	+36.37%
2018-12-31	AU$17.02 Million ≈ $12.04 Million	-1.35%
2017-12-31	AU$17.25 Million ≈ $12.21 Million	+38.42%
2016-12-31	AU$12.46 Million ≈ $8.82 Million	-4.89%
2015-12-31	AU$13.10 Million ≈ $9.27 Million	+68.93%
2014-12-31	AU$7.76 Million ≈ $5.49 Million	+111.81%
2013-12-31	AU$3.66 Million ≈ $2.59 Million	-76.54%
2012-12-31	AU$15.61 Million ≈ $11.04 Million	+6.87%
2011-12-31	AU$14.60 Million ≈ $10.33 Million	+6.09%
2010-12-31	AU$13.77 Million ≈ $9.74 Million	-1.17%
2009-12-31	AU$13.93 Million ≈ $9.86 Million	+6.69%
2008-12-31	AU$13.06 Million ≈ $9.24 Million	+77.82%
2007-12-31	AU$7.34 Million ≈ $5.20 Million	+1397.06%
2006-12-31	AU$-566.06K ≈ $-400.52K	-104.99%
2005-12-31	AU$11.34 Million ≈ $8.02 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Cyclopharm Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 6220402500.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Common Stock	AU$87.07 Million	321.17%
Other Comprehensive Income	AU$5.11 Million	18.86%
Total Equity	AU$27.11 Million	100.00%

Cyclopharm Ltd Competitors by Market Cap

The table below lists competitors of Cyclopharm Ltd ranked by their market capitalization.

Company	Market Cap
QPM Energy Ltd AU:QPM	$50.41 Million
Hilbert Group AB Series B ST:HILB-B	$50.44 Million
Thonburi Medical Centre Public Company Limited BK:KDH	$50.45 Million
Unlu Yatirim Holding AS IS:UNLU	$50.46 Million
Sirios Resources Inc. V:SOI	$50.38 Million
Ozerden Plastik Sanayi IS:OZRDN	$50.37 Million
Vinyl Chemicals (India) Limited NSE:VINYLINDIA	$50.35 Million
Helixmith Co. Ltd KQ:084990	$50.34 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Cyclopharm Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 42,729,869 to 27,111,058, a change of -15,618,811 (-36.6%).
Net loss of 17,219,906 reduced equity.
Other comprehensive income increased equity by 1,601,095.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	AU$-17.22 Million	-63.52%
Other Comprehensive Income	AU$1.60 Million	+5.91%
Total Change	AU$-	-36.55%

Book Value vs Market Value Analysis

This analysis compares Cyclopharm Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 2.30x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2006-12-31	AU$-0.02	AU$0.57	x
2007-12-31	AU$0.25	AU$0.57	x
2008-12-31	AU$0.43	AU$0.57	x
2009-12-31	AU$0.38	AU$0.57	x
2010-12-31	AU$0.37	AU$0.57	x
2011-12-31	AU$0.41	AU$0.57	x
2012-12-31	AU$0.34	AU$0.57	x
2013-12-31	AU$0.06	AU$0.57	x
2014-12-31	AU$0.13	AU$0.57	x
2015-12-31	AU$0.23	AU$0.57	x
2016-12-31	AU$0.22	AU$0.57	x
2017-12-31	AU$0.25	AU$0.57	x
2018-12-31	AU$0.25	AU$0.57	x
2019-12-31	AU$0.34	AU$0.57	x
2020-12-31	AU$0.22	AU$0.57	x
2021-12-31	AU$0.48	AU$0.57	x
2022-12-31	AU$0.40	AU$0.57	x
2023-12-31	AU$0.35	AU$0.57	x
2024-12-31	AU$0.42	AU$0.57	x
2025-12-31	AU$0.25	AU$0.57	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Cyclopharm Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -63.52%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -53.27%
• Asset Turnover: 0.70x
• Equity Multiplier: 1.70x
Recent ROE (-63.52%) is below the historical average (-3.49%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2005	13.95%	17.34%	0.43x	1.85x	AU$448.03K
2006	0.00%	19.63%	1.14x	0.00x	AU$2.08 Million
2007	15.41%	10.17%	1.01x	1.50x	AU$397.02K
2008	13.46%	16.14%	0.59x	1.42x	AU$451.51K
2009	14.68%	15.59%	0.67x	1.41x	AU$651.63K
2010	3.27%	4.76%	0.43x	1.61x	AU$-926.51K
2011	-6.55%	-9.27%	0.48x	1.46x	AU$-2.42 Million
2012	-6.69%	-9.72%	0.50x	1.39x	AU$-2.60 Million
2013	-21.30%	-6.56%	1.32x	2.46x	AU$-1.15 Million
2014	52.42%	33.75%	1.10x	1.41x	AU$3.29 Million
2015	36.58%	38.09%	0.76x	1.26x	AU$3.48 Million
2016	7.15%	6.20%	0.88x	1.32x	AU$-354.81K
2017	-8.84%	-11.56%	0.56x	1.36x	AU$-3.25 Million
2018	-0.21%	-0.26%	0.57x	1.38x	AU$-1.74 Million
2019	-12.55%	-20.69%	0.43x	1.40x	AU$-5.23 Million
2020	-35.31%	-41.18%	0.52x	1.65x	AU$-7.76 Million
2021	-11.70%	-28.47%	0.32x	1.29x	AU$-9.35 Million
2022	-18.10%	-28.47%	0.47x	1.36x	AU$-10.27 Million
2023	-14.57%	-17.85%	0.57x	1.42x	AU$-7.93 Million
2024	-30.89%	-47.87%	0.44x	1.45x	AU$-17.47 Million
2025	-63.52%	-53.27%	0.70x	1.70x	AU$-19.93 Million

Industry Comparison

This section compares Cyclopharm Ltd's net assets metrics with peer companies in the Medical Distribution industry.

Industry Context

Industry: Medical Distribution
Average net assets among peers: $281,223,974
Average return on equity (ROE) among peers: -9.97%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Cyclopharm Ltd (CYC)	AU$27.11 Million	13.95%	0.70x	$50.40 Million
Ebos Group Ltd (EBO)	$94.15 Million	10.96%	0.46x	$2.45 Billion
Mayne Pharma Group Ltd (MYX)	$1.01 Billion	-27.53%	0.61x	$134.52 Million
Paragon Care Ltd (PGC)	$1.94 Million	-84.65%	0.24x	$163.97 Million
Sigma Healthcare Ltd (SIG)	$14.73 Million	61.36%	3.36x	$22.54 Billion

About Cyclopharm Ltd

AU:CYC Australia Medical Distribution

Market Cap

$50.40 Million

AU$71.23 Million AUD

Market Cap Rank

#21906 Global

#785 in Australia

Share Price

AU$0.57

Change (1 day)

+0.89%

52-Week Range

AU$0.54 - AU$1.23

All Time High

AU$3.26